Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01142128 · ClinicalTrials.gov registry record · Phase 1
Viokase 16, Viokase16 Plus Nexium and Nexium Alone
A Phase 1 study, sponsored by University of Florida.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01142128 is a Phase 1 study that was terminated before completion, run by University of Florida. The registered enrollment target is 12 participants.
The verdict
NCT01142128, a Phase 1 study, was terminated before completion, sponsored by University of Florida.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
Our primary hypothesis is that the addition of Nexium to Viokase 16 will decrease the chronic abdominal pain in patients with small duct chronic pancreatitis in a superior fashion compared to Viokase 16 plus placebo or to Nexium alone. A secondary hypothesis would be an increase in quality of life. Our objective is to elucidate the role of Nexium in the control of pancreatic pain, quality of life, and narcotic usage alone or when added to Viokase 16. Our endpoints are the reduction of abdominal pain, decreased pain medication usage, decreased ER visits and decreased hospital admissions for abdominal pain.
Interventions
- DRUG Nexium (esomeprazole magnesium)
- DRUG Placebo to Nexium
- DRUG Viokase 16 (pancrelipase) + Nexium
- DRUG Viokase 16 + placebo to Nexium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2009-02 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01142128
The ClinicalTrials.gov registry entry for NCT01142128 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Nexium (esomeprazole magnesium) is the first listed.
NCT01142128 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01142128 about?
NCT01142128 is a clinical study titled "Viokase 16, Viokase16 Plus Nexium and Nexium Alone". Our primary hypothesis is that the addition of Nexium to Viokase 16 will decrease the chronic abdominal pain in patients with small duct chronic pancreatitis in a superior fashion compared to Viokase 16 plus placebo or to Nexium alone. A secondary hypothesis would be an increase in quality of life. ...
What is the current status of trial NCT01142128?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2009-02. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01142128?
The interventions under investigation include: Nexium (esomeprazole magnesium) (DRUG), Placebo to Nexium (DRUG), Viokase 16 (pancrelipase) + Nexium (DRUG), Viokase 16 + placebo to Nexium (DRUG).
Who is sponsoring clinical trial NCT01142128?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.